GNR-060
Phase 3Biologic
GNR-060 is one of 15 biologic programs targeting ST Elevation Myocardial Infarction. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in ST Elevation Myocardial Infarction
#DrugCompanyPhaseTrials
1Colcrys
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Farxiga
AstraZenecaApproved
Adenocard
AstellasApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Jardiance
Boehringer IngelheimApproved
Kengreal
Chiesi Farmaceutici S.p.A.Approved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Inomax
MMallinckrodt
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GNR-060. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- AAO GENERIUM